A randomized clinical trial of one-dose versus accelerated two-dose schedule for hepatitis A virus revaccination among people with HIV who were non-responders or had seroreversion after primary HAV vaccination.
Guan-Jhou ChenHsin-Yun SunKuan-Yin LinSzu-Min HsiehYu-Chung ChuangWang-Da LiuYu-Shan HuangSung-Ching PanUn-In WuAristine ChengYi-Chia HuangCheng-Hsin WuYi-Ching SuWen-Chun LiuSui-Yuan ChangChien-Ching HungPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Two-doses HAV revaccination administered four weeks apart yielded similar serological responses as one-dose revaccination among PWH who were non-responders or had seroreversion after primary HAV vaccination. Two-dose revaccination schedule generated significantly higher anti-HAV antibody titers and were more likely to elicit serological responses at week 48 among PWH who were non-responders to primary HAV vaccination.